|
Mr. Wavle became a member of our Board of Directors in June 2006. Mr. Wavle has more than thirty-five years of experience in the health care field, serving in senior management positions since 1974. He has operational experience in both a large pharmaceutical company and a major biotechnology firm. Since 2004, Mr. Wavle has been a member of the Board of Directors of Polymerix Corporation, a privately-held, development stage medical device and specialty pharmaceutical company utilizing therapeutic polymer technology. From 1997 to 2003, he served as Chairman, President & CEO of Therics, Inc., a high-technology healthcare company. In addition, from 2001 to 2003, he served a President of Molecumetics, Ltd., a drug discovery company. He also served as President of Tredegar Biotech from 2000 to 2003. At that time, Molecumetics, Ltd. was a subsidiary of Tredegar Corporation, as was Therics, which became a Tredegar subsidiary in 1999. From 1987 until his retirement in 1992, Mr. Wavle served as President andlater as CEO of Centocor, Inc., where he guided the corporation's transition from a diagnostics firm into a multinational biopharmaceutical company with manufacturing and sales organizations in the United States and Europe. From 1981 to 1987, he served as President of Parke-Davis, the pharmaceutical unit of Warner-Lambert, where he was responsible for manufacturing, marketing and sales, as well as worldwide pharmaceutical research. Earlier, he was Senior Vice President & General Counsel of Warner-Lambert Company. Mr. Wavle holds a B.A. from Adelphi University, a J.D. from Georgetown University, and an L.L.M. in Internations Law from New York University.
| 